TY - JOUR
KW - Adult
KW - Buprenorphine/therapeutic use
KW - Central Nervous System Stimulants/adverse effects
KW - Female
KW - Humans
KW - Male
KW - Methamphetamine/adverse effects
KW - Opiate Substitution Treatment
KW - Opioid-Related Disorders/drug therapy
KW - Recurrence
KW - Substance Abuse Treatment Centers
KW - Washington
KW - Buprenorphine, methamphetamine
KW - opioid use disorder
KW - Stimulants
AU - J. I. Tsui
AU - J. Mayfield
AU - E. C. Speaker
AU - S. Yakup
AU - R. Ries
AU - H. Funai
AU - B. G. Leroux
AU - J. O. Merrill
A1 - 
AD - Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA. Electronic address: tsuij@uw.edu.; Washington State Department of Social and Health Services, Olympia, WA, USA.; Washington State Department of Social and Health Services, Olympia, WA, USA.; Washington State Department of Social and Health Services, Olympia, WA, USA.; Department of Psychiatry, University of Washington School of Medicine, Seattle, WA, USA.; Washington State Health Care Authority, Olympia, WA.; Department of Biostatistics, University of Washington, Seattle, WA, USA.; Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
BT - Journal of substance abuse treatment
C5 - Opioids & Substance Use
CY - United States
DO - 10.1016/j.jsat.2019.10.005
JF - Journal of substance abuse treatment
LA - eng
M1 - Journal Article
PB - Elsevier Inc
PP - United States
PY - 2020
SN - 1873-6483; 0740-5472
SP - 80
EP - 85
EP - 
T1 - Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine
T2 - Journal of substance abuse treatment
TI - Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine
U1 - Opioids & Substance Use
U2 - 31810594
U3 - 10.1016/j.jsat.2019.10.005
VL - 109
VO - 1873-6483; 0740-5472
Y1 - 2020
Y2 - Feb
ER -